211 related articles for article (PubMed ID: 21963792)
1. Structural characterization of inhibitor complexes with checkpoint kinase 2 (Chk2), a drug target for cancer therapy.
Lountos GT; Jobson AG; Tropea JE; Self CR; Zhang G; Pommier Y; Shoemaker RH; Waugh DS
J Struct Biol; 2011 Dec; 176(3):292-301. PubMed ID: 21963792
[TBL] [Abstract][Full Text] [Related]
2. X-ray structures of checkpoint kinase 2 in complex with inhibitors that target its gatekeeper-dependent hydrophobic pocket.
Lountos GT; Jobson AG; Tropea JE; Self CR; Zhang G; Pommier Y; Shoemaker RH; Waugh DS
FEBS Lett; 2011 Oct; 585(20):3245-9. PubMed ID: 21907711
[TBL] [Abstract][Full Text] [Related]
3. Cellular inhibition of checkpoint kinase 2 (Chk2) and potentiation of camptothecins and radiation by the novel Chk2 inhibitor PV1019 [7-nitro-1H-indole-2-carboxylic acid {4-[1-(guanidinohydrazone)-ethyl]-phenyl}-amide].
Jobson AG; Lountos GT; Lorenzi PL; Llamas J; Connelly J; Cerna D; Tropea JE; Onda A; Zoppoli G; Kondapaka S; Zhang G; Caplen NJ; Cardellina JH; Yoo SS; Monks A; Self C; Waugh DS; Shoemaker RH; Pommier Y
J Pharmacol Exp Ther; 2009 Dec; 331(3):816-26. PubMed ID: 19741151
[TBL] [Abstract][Full Text] [Related]
4. Crystal structure of checkpoint kinase 2 in complex with NSC 109555, a potent and selective inhibitor.
Lountos GT; Tropea JE; Zhang D; Jobson AG; Pommier Y; Shoemaker RH; Waugh DS
Protein Sci; 2009 Jan; 18(1):92-100. PubMed ID: 19177354
[TBL] [Abstract][Full Text] [Related]
5. Checkpoint kinase inhibitors: a patent review (2009 - 2010).
Lainchbury M; Collins I
Expert Opin Ther Pat; 2011 Aug; 21(8):1191-210. PubMed ID: 21599421
[TBL] [Abstract][Full Text] [Related]
6. Anticancer therapy with checkpoint inhibitors: what, where and when?
Garrett MD; Collins I
Trends Pharmacol Sci; 2011 May; 32(5):308-16. PubMed ID: 21458083
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and evaluation of debromohymenialdisine-derived Chk2 inhibitors.
Saleem RS; Lansdell TA; Tepe JJ
Bioorg Med Chem; 2012 Feb; 20(4):1475-81. PubMed ID: 22285028
[TBL] [Abstract][Full Text] [Related]
8. Context-dependent cell cycle checkpoint abrogation by a novel kinase inhibitor.
Massey AJ; Borgognoni J; Bentley C; Foloppe N; Fiumana A; Walmsley L
PLoS One; 2010 Oct; 5(10):e13123. PubMed ID: 20976184
[TBL] [Abstract][Full Text] [Related]
9. Drug discovery targeting Chk1 and Chk2 kinases.
Zhou BB; Sausville EA
Prog Cell Cycle Res; 2003; 5():413-21. PubMed ID: 14593735
[TBL] [Abstract][Full Text] [Related]
10. UCN-01 inhibits p53 up-regulation and abrogates gamma-radiation-induced G(2)-M checkpoint independently of p53 by targeting both of the checkpoint kinases, Chk2 and Chk1.
Yu Q; La Rose J; Zhang H; Takemura H; Kohn KW; Pommier Y
Cancer Res; 2002 Oct; 62(20):5743-8. PubMed ID: 12384533
[TBL] [Abstract][Full Text] [Related]
11. Checkpoint kinase inhibitors: a review of the patent literature.
Janetka JW; Ashwell S
Expert Opin Ther Pat; 2009 Feb; 19(2):165-97. PubMed ID: 19441917
[TBL] [Abstract][Full Text] [Related]
12. Differential roles of checkpoint kinase 1, checkpoint kinase 2, and mitogen-activated protein kinase-activated protein kinase 2 in mediating DNA damage-induced cell cycle arrest: implications for cancer therapy.
Xiao Z; Xue J; Sowin TJ; Zhang H
Mol Cancer Ther; 2006 Aug; 5(8):1935-43. PubMed ID: 16928813
[TBL] [Abstract][Full Text] [Related]
13. Identification of a Bis-guanylhydrazone [4,4'-Diacetyldiphenylurea-bis(guanylhydrazone); NSC 109555] as a novel chemotype for inhibition of Chk2 kinase.
Jobson AG; Cardellina JH; Scudiero D; Kondapaka S; Zhang H; Kim H; Shoemaker R; Pommier Y
Mol Pharmacol; 2007 Oct; 72(4):876-84. PubMed ID: 17616632
[TBL] [Abstract][Full Text] [Related]
14. CCT241533 is a potent and selective inhibitor of CHK2 that potentiates the cytotoxicity of PARP inhibitors.
Anderson VE; Walton MI; Eve PD; Boxall KJ; Antoni L; Caldwell JJ; Aherne W; Pearl LH; Oliver AW; Collins I; Garrett MD
Cancer Res; 2011 Jan; 71(2):463-72. PubMed ID: 21239475
[TBL] [Abstract][Full Text] [Related]
15. Identification and characterisation of 2-aminopyridine inhibitors of checkpoint kinase 2.
Hilton S; Naud S; Caldwell JJ; Boxall K; Burns S; Anderson VE; Antoni L; Allen CE; Pearl LH; Oliver AW; Wynne Aherne G; Garrett MD; Collins I
Bioorg Med Chem; 2010 Jan; 18(2):707-18. PubMed ID: 20022510
[TBL] [Abstract][Full Text] [Related]
16. Potentiation of the novel topoisomerase I inhibitor indenoisoquinoline LMP-400 by the cell checkpoint and Chk1-Chk2 inhibitor AZD7762.
Aris SM; Pommier Y
Cancer Res; 2012 Feb; 72(4):979-89. PubMed ID: 22189968
[TBL] [Abstract][Full Text] [Related]
17. Fragment-based screening maps inhibitor interactions in the ATP-binding site of checkpoint kinase 2.
Silva-Santisteban MC; Westwood IM; Boxall K; Brown N; Peacock S; McAndrew C; Barrie E; Richards M; Mirza A; Oliver AW; Burke R; Hoelder S; Jones K; Aherne GW; Blagg J; Collins I; Garrett MD; van Montfort RL
PLoS One; 2013; 8(6):e65689. PubMed ID: 23776527
[TBL] [Abstract][Full Text] [Related]
18. Current inhibitors of checkpoint kinase 2.
Nguyen TN; Tepe JJ
Curr Med Chem; 2011; 18(28):4368-74. PubMed ID: 21861812
[TBL] [Abstract][Full Text] [Related]
19. Targeting chk2 kinase: molecular interaction maps and therapeutic rationale.
Pommier Y; Sordet O; Rao VA; Zhang H; Kohn KW
Curr Pharm Des; 2005; 11(22):2855-72. PubMed ID: 16101442
[TBL] [Abstract][Full Text] [Related]
20. The checkpoint kinases Chk1 and Chk2 regulate the functional associations between hBRCA2 and Rad51 in response to DNA damage.
Bahassi EM; Ovesen JL; Riesenberg AL; Bernstein WZ; Hasty PE; Stambrook PJ
Oncogene; 2008 Jun; 27(28):3977-85. PubMed ID: 18317453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
